Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Aug 9–Aug 16, 2026)

· 1 min read

Here’s what’s on the biotech calendar for August 9–August 16: 0 FDA decision dates, 3 trial catalysts, and 13 earnings reports from tracked companies.

🧪 Trial Catalysts & Milestones

  • GILD — 2026-08-09: Accelerated ART Initiation for PWHIV Who Are Out of Care
  • ACRV — 2026-08-12: Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
  • OSTX — 2026-08-12: Polymeric Micellar Paclitaxel-Based Combination Therapy for Advanced Biliary Tract Cancer

📊 Earnings This Week

  • SLS — 2026-08-10 (est. EPS -0.0505)
  • SPRO — 2026-08-10 (est. EPS -0.1734)
  • ADCT — 2026-08-10 (est. EPS -0.2101)
  • MAIA — 2026-08-10 (est. EPS -0.1122)
  • ORIC — 2026-08-10 (est. EPS -0.3659)
  • APGE — 2026-08-10 (est. EPS -1.0925)
  • BHVN — 2026-08-10 (est. EPS -0.7417)
  • VERU — 2026-08-10 (est. EPS -0.3264)
  • AIM — 2026-08-12 (est. EPS -0.1717)
  • CADL — 2026-08-12 (est. EPS -0.2384)
  • IBRX — 2026-08-12 (est. EPS -0.0884)
  • SPRO — 2026-08-12 (est. EPS -0.1734)
  • OSTX — 2026-08-13 (est. EPS -0.2101)

📡 Run-up Radar Highlights

Stocks entering the pre-catalyst window with the strongest setups (full radar is a Premium feature):

  • CAPR — BLA in 13 days, score 73/100
  • ZYME — NDA in 16 days, score 48/100
  • JAZZ — sBLA in 16 days, score 48/100

📈 Last Week’s Biggest Gainers

  • BRVE +65.56% (volume 0.0x average)
  • IOVA +43.09% (volume 4.9x average)
  • TEAM +35.31% (volume 4.0x average)
  • INSM +33.86% (volume 3.1x average)
  • DOCS +32.62% (volume 15.3x average)

Track your tickers on the BioRadar dashboard →

This digest is for informational purposes only and is not investment advice. Always do your own research.

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.